Houston, January 24, 2026
Nexalin Technology, based in Houston, has received a notification from Nasdaq regarding its compliance with minimum bid price requirements. This notification means the company must ensure its stock closes at $1.00 or above for at least ten consecutive days within a 180-day period to maintain its listing. The company is committed to regaining compliance while continuing its mission to innovate in neurostimulation for mental health. This situation highlights the resilience and strategic focus characteristic of Houston’s entrepreneurial landscape.
Houston Innovator Nexalin Technology Addresses Nasdaq Listing Status
Houston, TX – In the dynamic landscape of national capital markets, publicly traded companies periodically receive notifications regarding their compliance with listing standards. Recently, Houston-based Nexalin Technology, a pioneer in neurostimulation products, announced the receipt of a notification letter from the Nasdaq Stock Market LLC dated January 21, 2026. This communication pertains to the company’s compliance with Nasdaq’s minimum bid price requirement for continued listing. For a local enterprise engaged in critical health innovation, this presents an opportunity to underscore their commitment to operational excellence and strategic financial management.
The spirit of entrepreneurial innovation is a cornerstone of Houston’s robust economy, often fueled by companies that seek wider investment and visibility through public markets. Businesses like Nexalin Technology, striving to make a significant impact through advanced technology, frequently navigate the rigorous requirements of exchanges like Nasdaq. Their proactive approach to addressing this notification exemplifies the resilience often found within the Texas TX entrepreneurs community, a determination to uphold market standards while continuing their mission.
Nexalin Technology’s Nasdaq Standing
Nexalin Technology, Inc. received a notification letter from the Nasdaq Stock Market LLC on January 21, 2026, indicating that the company is not in compliance with the minimum bid price requirement for continued listing, as outlined under Nasdaq Listing Rule 5550(a)(2). This rule requires listed securities to maintain a minimum bid price of $1.00 per share. The deficiency was noted after the company’s shares closed below this threshold for 30 consecutive business days.
Following this notification, Nexalin Technology has been granted a period of 180 calendar days, specifically until July 20, 2026, to regain compliance. To meet this requirement, the company’s shares must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. It is important to note that the receipt of this notification does not have an immediate effect on the listing of Nexalin Technology’s shares, which will continue to trade uninterrupted on Nasdaq under the ticker symbol “NXL”.
Innovation at the Core of NeuroHealth
Nexalin Technology, headquartered in Houston, is at the forefront of developing innovative neurostimulation products designed to address the Nationwide mental health epidemic. The company specializes in non-invasive, frequency-based waveform devices that support the normalization of neurochemicals in the brain to provide relief for conditions such as anxiety and insomnia, all without the need for medication. This commitment to non-pharmacological treatments represents a significant advancement in bioelectronic medical technology.
The company’s Gen-2 15 milliamp neurostimulation device has achieved significant international recognition, having received regulatory approvals in several countries including China, Brazil, Oman, and Israel. Beyond its current applications, Nexalin Technology is also exploring the potential of its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology for addressing other neurodegenerative conditions, including Alzheimer’s disease, with clinical development efforts underway. This dedication to research and development underscores the company’s mission to enhance brain health globally.
Navigating Market Challenges with Strategic Focus
In response to the Nasdaq notification, Nexalin Technology has articulated a clear strategy aimed at regaining compliance. The company intends to continuously monitor its bid price and is actively considering various measures to enhance its financial position and operational results. These efforts are designed to counteract any short-term adverse effects on its trading price and cure the deficiency within the stipulated timeframe. This proactive stance reflects a dedication to sound corporate governance and investor confidence.
Notably, Nexalin Technology has indicated that it is not currently considering a reverse stock split as a means to regain compliance. This decision highlights a careful evaluation of available options, demonstrating a prudent approach to financial management that seeks sustainable solutions rather than immediate, potentially dilutive, actions. Such strategic planning is characteristic of well-managed Houston small business entities committed to long-term value creation.
The Significance of a Nasdaq Listing
Being listed on the Nasdaq Stock Market carries considerable benefits for companies, especially those in the technology and biotechnology sectors. Nasdaq is recognized as a preferred marketplace for technology and biotechnology stocks, offering increased visibility and exposure to a diverse pool of investors, both regional and international. This enhanced visibility can be crucial for a company like Nexalin Technology, which is developing advanced medical devices for a global market.
A Nasdaq listing also provides companies with access to capital, enabling them to fund research, development, and expansion initiatives. The exchange’s stringent financial, liquidity, and corporate governance requirements help ensure a level of credibility and transparency that can attract significant private investment. For innovative firms in the Houston TX business landscape, maintaining a presence on such a prestigious exchange can be a testament to their growth potential and adherence to high market standards, fostering overall economic growth.
Fostering Growth in Houston’s Business Landscape
The journey of companies like Nexalin Technology illustrates the vibrant entrepreneurial spirit prevalent in Houston. The city’s supportive ecosystem allows innovative firms to flourish, from initial concept to national and international market presence. The ability of Texas TX entrepreneurs to develop cutting-edge solutions, like those in neurostimulation, and then navigate the complexities of national capital markets, showcases the strength and adaptability of the local economy.
Limited regulatory hurdles and a business-friendly environment are often cited as catalysts for economic growth, encouraging startups and established companies alike to innovate and expand. Nexalin Technology’s ongoing efforts to meet Nasdaq’s requirements, while continuing to advance its neurohealth mission, embody this spirit of resilience and achievement. Their success and continued presence on Nasdaq contribute to Houston’s reputation as a hub for scientific and technological progress.
As Nexalin Technology works to resolve its Nasdaq listing status, its story serves as a valuable insight into the challenges and triumphs faced by innovative companies. Their commitment to improving global mental health through advanced technology, coupled with their strategic approach to market compliance, reinforces the positive trajectory of Houston’s economic landscape. Supporting local innovation and staying informed about the progress of such companies are crucial for anyone invested in Houston’s continued economic vibrancy. Engage with local businesses, explore their contributions, and champion the spirit of ingenuity that defines our community’s future.
FAQs about Nexalin Technology’s Nasdaq Listing Status Notification
- What notification did Nexalin Technology receive from Nasdaq?
- Nexalin Technology received a notification letter from the Nasdaq Stock Market LLC dated January 21, 2026, indicating non-compliance with the minimum bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).
- What is the Nasdaq minimum bid price requirement?
- The Nasdaq minimum bid price requirement stipulates that a listed security must maintain a minimum bid price of $1.00 per share.
- What is the reason for Nexalin Technology’s non-compliance?
- The non-compliance stems from Nexalin Technology’s shares closing below the $1.00 minimum bid price for 30 consecutive business days.
- What is the deadline for Nexalin Technology to regain compliance?
- Nexalin Technology has been granted 180 calendar days, until July 20, 2026, to regain compliance.
- How can Nexalin Technology regain compliance?
- To regain compliance, Nexalin Technology’s shares must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days.
- Does this notification immediately affect the trading of Nexalin Technology’s shares?
- No, the notification has no immediate effect on the listing of Nexalin Technology’s shares, which will continue to trade uninterrupted on Nasdaq under the ticker “NXL”.
- Is Nexalin Technology considering a reverse stock split?
- No, Nexalin Technology has stated it is not currently considering a reverse stock split.
- What is Nexalin Technology’s core business?
- Nexalin Technology designs and develops innovative neurostimulation products to combat the global mental health epidemic, specifically non-invasive, FDA-cleared frequency-based waveform devices for anxiety and insomnia.
- Where is Nexalin Technology headquartered?
- Nexalin Technology is headquartered in Houston, TX.
Key Features of Nexalin Technology’s Nasdaq Listing Status Notification
| Feature | Details | Scope |
|---|---|---|
| Date of Notification | January 21, 2026 | Nationwide |
| Issuing Authority | Nasdaq Stock Market LLC | Nationwide |
| Rule Violation | Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)) | Nationwide |
| Required Bid Price | $1.00 per share | Nationwide |
| Duration of Non-Compliance | 30 consecutive business days below $1.00 bid price | Nationwide |
| Compliance Period Granted | 180 calendar days | Nationwide |
| Compliance Deadline | July 20, 2026 | Nationwide |
| Action for Compliance | Closing bid price of at least $1.00 for a minimum of 10 consecutive trading days | Nationwide |
| Immediate Impact on Trading | None; shares continue to trade uninterrupted under “NXL” | Nationwide |
| Consideration of Reverse Stock Split | Not currently considering | Nationwide |
| Company Headquarters | Houston, TX | State-level |
| Core Business | Non-invasive neurostimulation products for mental health (anxiety, insomnia) | Nationwide |
| International Approvals | Gen-2 device approved in China, Brazil, Oman, and Israel | Nationwide |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE HOUSTON TX WRITER
The HOUSTON STAFF WRITER represents the experienced team at HEREHouston.com, your go-to source for actionable local news and information in Houston, Harris County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Houston Livestock Show and Rodeo, Art Car Parade, and Chevron Houston Marathon. Our coverage extends to key organizations like the Greater Houston Partnership and Houston Area Urban League, plus leading businesses in energy and healthcare that power the local economy such as ExxonMobil, Schlumberger, and Houston Methodist. As part of the broader HERE network, including HEREAustinTX.com, HERECollegeStation.com, HEREDallas.com, and HERESanAntonio.com, we provide comprehensive, credible insights into Texas's dynamic landscape.
